Understanding how amyloid peptides clump together in Alzheimer's disease
Pathways and interactions accounting for the oligomerization of amyloid peptides
This study is looking at how certain proteins in the brain clump together in Alzheimer's disease and how these clumps can harm brain cells, with the hope of finding new ways to stop or slow down this process to help people with Alzheimer's.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New Jersey Institute of Technology NIH-funded |
| Lab location | 1 site (Newark, United States) |
| Project ID | NIH-10580438 on NIH RePORTER |
What this research studies
This research investigates the process by which amyloid peptides aggregate into harmful structures in Alzheimer's disease. It focuses on the interactions between these aggregates and cell membranes, which can lead to cell damage. By using advanced molecular simulations and laboratory experiments, the study aims to uncover the mechanisms behind the formation of these aggregates, particularly how they form on existing fibrils. The ultimate goal is to develop new treatments that can prevent or reduce the aggregation of these peptides, potentially slowing the progression of Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of developing Alzheimer's disease or those in the early stages of the condition.
Not a fit: Patients with advanced Alzheimer's disease or those who do not have amyloid-related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new preventive treatments for Alzheimer's disease, improving the quality of life for patients.
How similar studies have performed: Previous research has shown promise in understanding amyloid aggregation, but this approach focusing on secondary nucleation is relatively novel.
Where this research is happening
Newark, United States
- New Jersey Institute of Technology — Newark, United States (Active)
Researchers
- Principal investigator: Dias, Cristiano Luis — New Jersey Institute of Technology
- Study coordinator: Dias, Cristiano Luis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.